Mel-18, a polycomb group (PcG) protein, has been suggested as a tumor suppressor in human breast cancer. Previously, we reported that Mel-18 has antiproliferative activity in breast cancer cells. However, its functional mechanism has not been fully elucidated. Here, we investigated the role of Mel-18 in human breast cancer. We saw an inverse correlation between Mel-18 and phospho-Akt, which were expressed at low and high levels, respectively, in primary breast tumor tissues from 40 breast cancer patients. The effect of Mel-18 on cell growth was examined in two breast cancer cell lines, SK-BR-3 and T-47D, which express relatively low and high levels of endogenous Mel-18, respectively. On Mel-18 overexpression in SK-BR-3 cells, cell growth was attenuated and G 1 arrest was observed. Likewise, suppression of Mel-18 by antisense expression in T-47D cells led to enhanced cell growth and accelerated G 1 -S phase transition. In these cells, cyclindependent kinase (Cdk)-4 and Cdk2 activities were affected by Mel-18, which were mediated by changes in cyclin D1 expression and p27
Mel-18 Negatively Regulates INK4a/ARF-Independent Cell Cycle Progression via Akt Inactivation in Breast Cancer
Jeong-Yeon Lee, 1 Ki-Seok Jang, 1 Dong-Hui Shin, 1 Mi-Yun Oh, 1 Hyun-Jun Kim,
Introduction
Polycomb group (PcG) proteins are highly conserved factors that act as transcriptional repressors. They were originally identified in Drosophila and play a crucial role in maintaining repression of homeotic genes during development (1) . PcG proteins control many diverse biological processes, including cellular differentiation, proliferation, and tumorigenesis (2, 3) . They form multimeric protein complexes and epigenetically regulate many target genes through chromatin modification (2) . These proteins are classified into two distinct groups: one is the polycomb repressive complex 2 group, which is thought to initiate repression by methylating histone H3 lysine 9 and 27, and another is the polycomb repressive complex 1 group, which is considered to be involved in maintenance of repression (2, 3) .
Mel-18, also known as polycomb group ring finger protein, is a constituent of polycomb repressive complex 1. Mel-18 is highly homologous to Bmi-1 by sharing 57% amino acid identity and a zinc finger named RING at its NH 2 terminus. Wiederschain et al. (4) have recently reported that Bmi-1 and Mel-18 in HeLa cells compose nearly identical core proteins by sharing many constituents, such as Ring1, Ring2, RYBP, HPH1, HPH2, HPH3, CBX4, and CBX8. Despite their structural similarities, many studies report differences in their roles in cancer cell growth and survival. Unlike Bmi-1, which is overexpressed in various human tumors and generally accepted as a proto-oncogene (4-7), Mel-18 is shown to be either oncogenic or tumor suppressive, depending on the cancer system. Mel-18 was originally cloned from B16 mouse melanoma cells and their transcripts were shown to be highly expressed in many tumor cells including human melanoma and Hodgkin's lymphomas (8, 9) . Mel-18 and Bmi-1 are highly expressed in DAOY medulloblastoma cells and small hairpin RNA-mediated knockdown of either one or both of them in DAOY cells inhibits cancer cell growth in vitro and suppresses the growth of human medulloblastoma xenografts in vivo (4). However, markedly enhanced tumorigenicity has been shown in nude mice injected with NIH 3T3 cells overexpressing antisense mel-18, but not with sense construct (10) . We have also reported that Mel-18 directly interacts with cyclin D2 and knockdown of Mel-18 by antisense construct in T-47D breast cancer cells enhances cell proliferation (11) . Recently, Guo et al. (12) reported an inverse correlation between Mel-18 and Bmi-1 expression in breast cancer cell lines and primary human breast tumors. Furthermore, they have shown Mel-18 as a tumor suppressor in MCF7 breast cancer cells and suggested repression of Bmi-1 expression and downregulation of Akt activity as its mechanism. Therefore, the functional role of Mel-18 should be carefully interpreted within the context of a cancer system. Akt signaling plays a crucial role in many biological processes including cell proliferation and survival. Its aberrant activation contributes to tumor progression in many types of human cancer including breast cancer (13) . Akt promotes cell proliferation through its many downstream effectors. Particularly, Akt positively regulates G 1 to S transition in cell cycle progression through regulation of D-type cyclins and cyclin-dependent kinase (Cdk) inhibitors, such as p27 Kip1 , at the transcriptional level. Akt controls the canonical Wnt pathway (14, 15) . Akt-dependent phosphorylation of the Forkhead family transcription factors leads to their nuclear exclusion and, thus, inhibition of FoxO factor-mediated gene expression including p27
Kip1 (16, 17) and up-regulation of cyclin D1 (18) . Moreover, Akt regulates the stability and subcellular localization of G 1 regulators. Akt-dependent inactivation of glycogen synthase kinase-3h (GSK-3h) blocks cyclin D1 phosphorylation at Thr 286 , which protects cyclin D1 from proteolytic degradation (19) . Phosphorylation of p27 Kip1 at Thr 157 by Akt causes cytoplasmic retention, which blocks binding to nuclear Cdk2/cyclin E (20) (21) (22) . Similarly, p21
Cip1/WAF1 is retained in the cytoplasm on phosphorylation at Thr 145 by Akt (23) . Previously, we have reported that loss of Mel-18 expression accelerates cell proliferation of T-47D human breast cancer cells (11) . However, its exact mechanism remains undefined. To elucidate the growth regulatory mechanism of Mel-18, we investigated the effect of Mel-18 on cell cycle in breast cancer cells. In this study, we found that Mel-18 attenuated cell growth and caused G 1 arrest by down-regulation of cyclin D1 expression and p27
Kip1 phosphorylation at Thr 157 via inactivation of the Akt signaling pathway. Our data suggest that Mel-18 controls cell cycle as a negative regulator of Akt and may have a possibility of being the tumor suppressor gene in human breast cancer. Kip1 and h-catenin (BD Transduction Laboratories); Cy5-conjugated antimouse IgG (Jackson Immunoresearch); and h-actin and phycoerythrin-conjugated antirabbit IgG (Sigma).
Materials and Methods
Plasmids, transfection, and retroviral infection. Full-length Mel-18 cDNA in pOTB7 vector was purchased (clone MGC-10336; American Type Culture Collection). The retroviral vector pCL-IRES3-EGFP was a generous gift from Chang-Hwan Park (Hanyang University, Seoul, Korea). The p27 Kip1 DNLS mutant construct (24) was kindly provided by Incheol Shin (Hanyang University, Seoul, Korea). Mel-18 cDNA in pOTB7 was cut with BamHI and XhoI restriction enzymes, blunt-ended with Klenow, and subcloned into Xho I-cut and blunt-ended pCL-IRES3-EGFP vector. Subcloned Mel-18 cDNA clones in the forward and reverse orientations were used as expression and antisense constructs, respectively. H29D cells were transfected with each plasmid using Lipofectamine (Invitrogen). After 48-h transfection, the medium containing retroviruses was harvested, filtered through 0.45-Am filters, and transferred to target cells with 6 Ag/mL polybrene (Sigma) or stored in aliquots at À70jC for later use. The infected cells were transiently used in experiments or selected with 10 Ag/mL blasticidin S (Invitrogen) for 6 d, maintained with the medium containing 2 Ag/mL blasticidin S, and used as stable cells.
Cell proliferation assay. The CellTiter 96 nonradioactive cell proliferation assay kit (Promega) was used for measurement of cell proliferation. As described by the manufacturer, cells were seeded onto 96-well plates and incubated with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) dye solution at 37jC for 4 h, and stopped by addition of solubilization/stop solution. The formazan product was measured at 570-nm absorbance using a microplate reader (Bio-Rad).
Cell cycle analysis. Cells were trypsinized, washed once with ice-cold PBS, and fixed with 75% ethanol at À20jC for 2 h. After washing twice with PBS, cells were stained with 10 Ag/mL propidium iodide (Sigma) containing 1 mg/mL RNase at 37jC for 20 min in the dark and analyzed with FACSCalibur flow cytometer and CellQuest software (BD Biosciences).
Reverse transcription-PCR. Total RNA was isolated with Trizol (Invitrogen) and reverse transcription-PCR (RT-PCR) was done with Access RT-PCR system (Promega) according to the instructions of the manufacturers. The cDNA amplification was carried out using the GeneAmp PCR system (Perkin-Elmer) as follows: 94jC for 5 min, 22 to 28 cycles of 94jC for 1 min, 54jC to 58jC for 1 min, 72jC for 1.5 min, and 72jC for 10 min. The following specific primers were used for PCR reaction: cyclin D1, 5 ¶-AGCCATGGAACACCAGCTC-3 ¶ and 5 ¶-GCACCTCCAGCATCCAGGT-3 ¶; cyclin E, 5 ¶-ATACAGACCCACAGAGACAG-3 ¶ and 5 ¶-TGCCATCCACAGAAA-TACTT-3 ¶; p27 Immunoblotting and immunoprecipitation. Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer and immunoblotting was carried out as described (25) . For immunoprecipitation, 1 Ag of Cdk4 and Cdk2 antibodies was chemically cross-linked with 20 mmol/L dimethyl pimelimidate (Sigma) in 0.2 mol/L sodium tetraborate (pH 9.0) to 20 AL of protein A agarose (Upstate Biotechnology). Cell lysates (1 mg) and the cross-linked antibodies were immunoprecipitated as described (25) .
In vitro kinase assay. Total cell lysates were immunoprecipitated with anti-Cdk4 or anti-Cdk2 antibodies at 4jC for 16 h. Cell fractionation. Cell fractionation was carried out using NE-PER Nuclear and cytoplasmic extraction reagents (Pierce) as described by the manufacturer. Briefly, 2 Â 10 6 cells were pelleted and lysed in 200 AL of icecold CER I buffer and 11 AL of ice-cold CER II buffer. After centrifugation at 4jC for 5 min, the supernatant (cytoplasmic extract) was collected and the pellet was resuspended in 50 AL of ice-cold NER buffer and vortexed for 15 s every 10 min, for a total of 50 min. After centrifugation at 4jC for 10 min, the supernatant was collected as nuclear extract. The extracts were subjected to immunoblotting or stored at À80jC until use.
Immunofluorescence staining. Cells (1 Â 10 5 per chamber) were seeded onto a four-chamber slide glass (Lab-Tek II Chamber Slide System, Nalge Nunc International) for 16 h, washed with PBS, fixed with 4% paraformaldehyde for 30 min, and permeabilized with 0.2% Triton X-100 for 5 min. After blocking with 3% bovine serum albumin for 1 h, cells were stained with appropriate primary antibodies diluted 1:200 at 4jC for 16 h. Phycoerythrin-conjugated antirabbit IgG (1:200) and Cy5-conjugated antimouse IgG (1:200) were used as secondary antibodies. To visualize the nucleus, 4 ¶6-diamidino-2-phenylindole (DAPI) staining was also done as previously described (26) . Immunofluorescence was detected by fluorescence microscopy (Nikon).
Reporter assay. Cells were seeded at 1 Â 10 5 per well in a 12-well plate, and then transfected with 1 Ag of pTOP-FLASH, a T-cell factor/lymphoid enhancer factor (TCF/LEF) promoter, or pFOP-FLASH, a TOP mutant form (27), and h-gal cDNAs using FuGENE6 reagent (Roche Diagnostics Corp.). After incubation for 24 h, the cells were infected with retrovirus encoding empty vector or Mel-18 for 48 h. Luciferase activity, expressed as relative light units, was measured using Luciferase Assay system (Promega) and MicroLumat Plus LB96V luminometer (Berthold Technologies) and normalized by h-galactosidase activity.
Statistical analysis. The Western blot and RT-PCR band densities were determined using AlphaEase FC Software (AlphaInnotech, Inc.) and statistical analysis was done with Fisher's exact test or Student's t test using SPSS software (SPSS version 11.0).
Results
Loss of Mel-18 correlates with phosphorylated Akt in primary human breast cancer. Increased Akt activity plays a key role in cancer progression and it is frequently activated in various human cancers including breast cancer (28) . To investigate whether Mel-18 expression and Akt activity have correlation in human primary breast cancer, we tested Mel-18 expression and Akt phosphorylation at Ser 473 , a recognition site for Akt activation, in pairs of normal and tumor breast tissues from individual breast cancer patients by immunoblotting. Mel-18 was expressed in both normal and tumor tissues. However, 32 of 40 tumors showed significantly reduced Mel-18 expression compared with normal tissues (Fig. 1, top) . Furthermore, we found that the tumor cells, which have lower expression of Mel-18 compared with normal tissue, showed enhanced Akt phosphorylation (Fig. 1, bottom) . Akt phosphorylation was increased in 24 of 40 tumor tissues but total Akt expression remained unchanged. Our result shows an inverse correlation between Mel-18 and Akt activity in human clinical samples, suggesting that loss of Mel-18 may play an important role in breast cancer progression.
Mel-18 attenuates cell growth by G 1 arrest in human breast cancer. To examine the role of Mel-18 in human breast cancer cells, we first measured Mel-18 protein and mRNA levels in various human breast cancer cell lines by Western blot analysis and RT-PCR, respectively. In estrogen receptor-positive T-47D and MCF7 cell lines, Mel-18 was moderately or highly expressed, whereas in estrogen receptor-negative SK-BR-3, MDA-MB-231, and MDA-MB-435 cell lines, low expression was seen ( Fig. 2A) . Next, the role of Mel-18 in breast cancer cell proliferation was examined in two breast cancer cell lines, SK-BR-3 and T-47D cells, where endogenous Mel-18 expression levels are low and high, respectively. To overexpress or suppress Mel-18 expression in low-or highexpressing cells, we generated retroviral Mel-18 and Mel-18 antisense constructs, respectively. SK-BR-3 cells, which have low expression of Mel-18, were infected with retrovirus encoding Mel-18 cDNA and selected with blasticidin S. Mel-18 overexpression in the stable cells was confirmed by Western blot analysis (Fig. 2B , top left) and the effect of Mel-18 on cell growth was determined by MTT assay. There was an inverse relationship between Bmi-1 and Mel-18 on Mel-18 overexpression or suppression (Fig. 2B) , which is consistent with a previous report (12) . As shown in Fig. 2B (bottom left), cell growth was attenuated in Mel-18-overexpressing SK-BR-3 cell lines (P < 0.05, Student's t test). Because of the difficulty in long-term maintenance of the stable cells, attributed to the growth inhibitory effect of Mel-18, and comparable efficiency in Mel-18 transduction, all further experiments in this article were done after transient retroviral transduction. SK-BR-3 cells were retrovirally infected with Mel-18 for 24 hours and cell cycle was analyzed by flow cytometry after 72 hours. As seen in Fig. 2B (right) , the percentage of G 1 phase cells was increased and S phase was slightly reduced in the Mel-18-overexpressing cells (P < 0.05, Student's t test). Furthermore, we blocked Mel-18 expression in T-47D cells using a retrovirus encoding a Mel-18 antisense construct. As shown in Fig. 2C 
Mel-18-mediated G 1 arrest occurs by down-regulation of Cdk4 and Cdk2 activities via changes in cyclin D1, cyclin E, and p27
Kip1
, but not INK4a/ARF family genes. Because we observed changes in G 1 to S transition by Mel-18 overexpression or suppression (Fig. 2) , we examined whether Mel-18 affected Cdk4 and Cdk2 activities. In Mel-18-overexpressing SK-BR-3 cells, Cdk4 kinase activity was decreased whereas Cdk2 kinase activity was not changed (P = 0.001, Student's t test; Fig. 3A, left) . On knockdown of Mel-18 expression in T-47D cells, both Cdk4 and Cdk2 activities were augmented (P = 0.034 and P = 0.038, respectively, Student's t test; Fig. 3A, right) . Total amounts of Cdk4 and Cdk2 proteins were unchanged in both cell lines (Fig. 3A, Input) . We next explored the effect of Mel-18 on the expression of G 1 phase regulators, cyclins and Cdk inhibitors, which could affect Cdk4 and Cdk2 activities. In Mel-18-infected SK-BR-3 cells, cyclin D1 expression was down-regulated whereas cyclin E expression was unchanged (P < 0.001, Student's t test; Fig. 3B, left) . On the other hand, both cyclin D1 and cyclin E expressions were up-regulated by Mel-18 blockade in T-47D cells (P = 0.002 and P = 0.045, respectively, Student's t test; Fig. 3B, right) . In addition, total amount of p27
Kip1 remained unchanged, but phosphorylation of p27 Kip1 at Thr 157 , which is involved in cytoplasmic localization, was significantly reduced by Mel-18 overexpression in SK-BR-3 cells and enhanced by Mel-18 suppression in T-47D cells (P < 0.001 and P = 0.019, respectively, Student's t test; Fig. 3B ). Identical expression patterns were seen at the mRNA level when assessed by RT-PCR (cyclin D1 in SK-BR-3, P = 0.023; in T-47D, P = 0.023, Student's t test; Fig. 3C ). Because Mel-18 is known as a regulator of INK4a/ARF family (29-31), we also investigated p16 INK4a , p15 INK4b , and p14 ARF expressions in these cell lines. Although p15
INK4b was expressed in both cell lines, its expression remained unchanged by overexpression or suppression of Mel-18 ( Fig. 3B and C) . The protein level of p16
INK4a was not detected in both SK-BR-3 and T-47D cells (data not shown). Both protein and mRNA levels of p14 ARF were very weak in T-47D cells and its expression was unchanged in both SK-BR-3 and T-47D cell lines (data not shown). Next, we examined whether the changes seen with total protein were reflected in the association with G 1 phase Cdks. As shown in Fig. 3D (left) , on Mel-18 overexpression in SK-BR-3, the amount of Cdk4-associated cyclin D1 was decreased (P < 0.001, Student's t test). Moreover, the amount of Cdk4-associated p27 Kip1 was decreased whereas Cdk2-associated p27 Kip1 was increased as determined by coimmunoprecipitaion, suggesting that p27
Kip1 was shifted from Cdk4 to Cdk2 in Mel-18-overexpressing SK-BR-3 cells (P < 0.001 and P = 0.019, respectively, Student's t test). The amount of Cdk2-associated cyclin E remained unchanged. In T-47D cells, coimmunoprecipitation showed the increase in the amounts of both Cdk4-associated cyclin D1 and Cdk2-associated cyclin E (P = 0.023 and P = 0.016, Kip1 were quantified by immunoblotting. Representative of three independent experiments with similar results. Each blot density was quantified. * and **, P < 0.05, statistically significant increase and decrease, respectively (Student's t test).
respectively, Student's t test; Fig. 3D, right) . The amounts of both Cdk2-and Cdk4-associated p27 Kip1 were unchanged (Fig. 3D, right) . Therefore, these results indicate that Mel-18-mediated G 1 arrest is attributed to changes in G 1 cyclin expression and p27 Kip1 phosphorylation, but not in INK4a/ARF expressions, in human breast cancer cell lines.
Mel-18-induced G 1 arrest is mediated by the Akt signaling pathway. To understand the molecular mechanism involved in the Mel-18-mediated regulation of cyclin D1 expression and p27 Kip1 phosphorylation, we investigated the upstream signaling pathways of cell cycle regulators. Because we saw an inverse correlation between Mel-18 and Akt phosphorylation in primary breast cancer (Fig. 1) Fig. 4B ). Total amount of Akt was unchanged in both cells. Because cyclin D1 expression can also be regulated by the MAPK signaling pathway (33), we also investigated this pathway in Mel-18-or Mel-18 antisensetransduced breast cancer cell lines. Phosphorylation and total amount of Erk1/2 were unchanged in both cell lines (Fig. 4A  and B) . To confirm that the changes of cell cycle regulators were Akt-dependent effects in Mel-18 antisense-infected T-47D cells, we treated the cells with 40 Amol/L of LY294002, a phosphatidylinositol 3-kinase inhibitor, and/or 50 Amol/L of PD98059, a MEK inhibitor. As shown in Fig. 4C , the effect of Mel-18 antisense on cyclin D1 expression and p27
Kip1 phosphorylation was abrogated when cells were treated with LY294002 (lane 3 versus lane 2), but not with PD98059 (lane 4 versus lane 2; P = 0.008 and P = 0.009, respectively, Student's t test). Interestingly, endogenous expression of Mel-18 was up-regulated by LY294002 treatment (lane 3 versus lane 2). Likewise, the phosphatidylinositol 3-kinase inhibitor wortmannin also increased Mel-18 expression (data not shown). Collectively, these results show that the changes seen in cyclin D1 expression and p27
Kip1 phosphorylation by Mel-18 are mediated by the Akt signaling pathway but not by the Erk pathway.
Mel-18 blocks Akt-mediated cytoplasmic localization of p27 Kip1 . Direct phosphorylation of p27 Kip1 at Thr 157 by Akt is implicated in inhibition of its nuclear import (20) (21) (22) . Because we found that Mel-18 down-regulated p27
Kip1 phosphorylation at Thr 157 (Fig. 3A) , the effect of Mel-18 on subcellular localization of p27 Kip1 was examined. SK-BR-3 cells were infected with retroviral vector encoding each construct (control, Mel-18, p27 Kip1 DNLS mutant) or treated with 40 Amol/L LY294002. The overexpression of Mel-18 and p27
DNLS mutant and the Akt inhibition effect of LY294002 were confirmed by Western blot analysis (Fig. 5A) . We found that cytoplasmic p27
Kip1 expression was reduced and nuclear p27
Kip1 expression was enhanced by Mel-18 as determined by cytoplasmic and nuclear fractionations and immunoblotting (Fig. 5B) . To confirm these data, we also carried out immunofluorescence staining in these cells. Consistent with the above result, cytoplasmic p27
Kip1 was reduced in Mel-18-overexpressing SK-BR-3 cells (P < 0.05, Student's t test; Fig. 5C ). Therefore, these results suggest that Mel-18 affects Akt-mediated p27
Kip1 localization in human breast cancer.
Mel-18 inhibits the Akt-mediated Wnt signaling pathway. Because cyclin D1 expression was affected by Mel-18 at both protein and transcript levels ( Fig. 3B and C) and the Akt signaling pathway was implicated (Fig. 4C) , we tested whether the Aktmediated Wnt signaling pathway was involved in the regulation of cyclin D1 expression. In Mel-18-infected SK-BR-3 cells, GSK-3h Kip1 phosphorylation via the Akt signaling pathway but not the Erk pathway. A and B, transiently transduced SK-BR-3 and T-47D, prepared as in Fig. 3 , were subjected to immunoblotting to examine the changes in Akt and Erk expression and phosphorylation. The Western blot densities were measured and statistically analyzed with Student's t test. * and **, P < 0.05, statistically significant increase and decrease, respectively. C, four days after release from synchronization, T-47D cells were treated with 40 Amol/L LY294002 and/or 50 Amol/L PD98059 for 24 h, and subjected to immunoblotting with antibodies as indicated. Representative of three independent experiments with similar results. *, P < 0.05, statistically significant increase compared with lane 1 ; c and c c, P < 0.05, statistically significant increase and decrease compared with lane 2, respectively. phosphorylation at Ser 9 was diminished whereas total GSK-3h expression remained unchanged as determined by immunoblotting (Fig. 6A, left) . Likewise, enhanced GSK-3h phosphorylation at Ser 9 was seen in Mel-18 antisense-infected T-47D cells (Fig. 6A, right) . However, total h-catenin expression remained unchanged in both cell lines (Fig. 6A) . Because inhibition of GSK-3h phosphorylation implicates reduced nuclear h-catenin (15), we next investigated the subcellular localization of h-catenin on Mel-18 overexpression in SK-BR-3 cells. As shown in Fig. 6B , cytoplasmic h-catenin expression was increased and nuclear h-catenin expression was decreased by Mel-18 overexpression as assessed by biochemical fractionation of nuclear and cytoplasmic proteins and immunoblotting. Consistent with this result, enhanced localization of h-catenin in the cytoplasm was seen in Mel-18-overexpressing cells as determined by immunofluorescence staining (P < 0.05, Student's t test; Fig. 6C) . Furthermore, the reduction of nuclear h-catenin by Mel-18 in SK-BR-3 cells also reduced TCF/LEF promoter activity, as assessed by reporter assays with h-catenin-dependent TCF/LEF promoter (TOP-FLASH) and its mutant (FOP-FLASH; P = 0.01, Student's t test; Fig. 6D ). Taken together, Mel-18 effect on cyclin D1 transcription is mediated by the Akt-dependent canonical Wnt signaling pathway.
Discussion
In this study, we report that Mel-18 regulates cell cycle progression by down-regulation of the Akt signaling pathway in human breast cancer. In primary breast tumors, the expression of Mel-18 was inversely correlated with phosphorylation of Akt at Ser 473 , which is phosphorylated in activated Akt. Mel-18 expression was also correlated with the percentage of the G 1 phase population by regulating the activities of Cdk4 and Cdk2 in T-47D and SK-BR-3 breast cancer cell lines. Those Cdk activities were affected by changes in cyclin D1 expression and p27
Kip1 phosphorylation, but not in INK4a/ARF gene family. Cyclin D1 expression was regulated by the Akt-mediated Wnt signaling pathway, and cytoplasmic Fig. 4C . A, each cell lysate was subjected to immunoblotting with indicated antibodies. B, cells were fractionated and the amounts of nuclear and cytoplasmic p27
Kip1 were estimated by immunoblotting. p27 Kip1 D NLS mutant construct and LY294002 treatment were used as positive controls for cytoplasmic p27
Kip1 and nuclear p27 Kip1 , respectively. a-Tubulin and Sp1 were tested as controls of cytoplasmic and nuclear fractionations, respectively. C, cells were costained with anti-p27
Kip1 antibody coupled with Cy5-conjugated antimouse immunoglobulin (IgG; red) and anti-Mel-18 antibody coupled with phycoerythrinconjugated antirabbit IgG (white ). The efficiency of retroviral infection was determined by observation of green fluorescent protein (GFP ) expression (green ). To visualize the nucleus, DAPI staining was also done (blue ). The ratio of the cytoplasmic and nuclear p27
Kip1 expression was measured by counting 1,000 cells each in three independent experiments and the result was shown as percentage of total cells counted F SD (bottom). *, P < 0.05 (Student's t test).
retention of p27
Kip1 was reduced by inhibition of Akt-dependent phosphorylation at Thr 157 . Taken together, we show a linear relationship between Mel-18, Akt, and G 1 phase regulators.
The oncogenic properties of several PcG proteins such as Bmi-1, RNF2, and CBX7 are, at least in part, attributed to repression of Cdkn2a locus, the tumor-suppressive locus encoding INK4a and ARF proteins (2) . They can control G 1 -S transition in cell cycle progression and senescence via targeting INK4a/ARF locus (29, 34, 35) . Mel-18 has also been reported as an inhibitor of INK4a/ARF genes (29, 30) . However, a recent report shows that Mel-18 accelerates cellular senescence through down-regulation of Bmi-1 and up-regulation of its target genes, p16
INK4a and p14 ARF , in human fibroblast (31) . As we previously showed that Mel-18 interacts with cyclin D2 and inhibits the proliferative activity of cyclin D2 in breast cancer (11), we have further examined the role of Mel-18 in cell cycle progression. Here, we suggest that Mel-18 negatively regulates cell cycle of human breast cancer in a INK4a/ ARF-independent manner. The INK4a/ARF locus is frequently silenced in human primary breast tumors (36) (37) (38) . The expression levels of these genes were also very weak or undetectable in human breast cancer cell lines including T-47D (data not shown). Although their expression patterns were undetectable or remained unchanged, Mel-18 could affect the G 1 -S transition through changes in Cdk4 and Cdk2 activities via regulation of other G 1 phase regulators, particularly cyclin D1 and p27 Kip1 (Fig. 3) 18 and Akt, the significance of this study is that our focus is different from them. They suggest that Bmi-1 enhances Akt activity and Mel-18-mediated Bmi-1 down-regulation leads to inhibition its activity. Although, we did not look into the role of Bmi-1 in our system, we also show the relationship between Mel-18 expression and Akt activation both in vitro and in vivo. We found an inverse correlation between Mel-18 expression and Akt phosphorylation at Ser 473 in human primary breast cancer (Fig. 1 ). This result is Figure 6 . Mel-18 inhibits the Akt-mediated canonical Wnt pathway. A, transiently transduced SK-BR-3 and T-47D cells, as in Fig. 3 , were subjected to immunoblotting with indicated antibodies. B, Mel-18-infected SK-BR-3 cells were fractionated and the amounts of nuclear and cytoplasmic h-catenin expression were estimated by Western blot analysis. a-Tubulin and Sp1 were tested as controls of cytoplasmic and nuclear fractions, respectively. C, cells were stained with h-catenin antibody coupled with Cy5-conjugated antimouse IgG (red ) and Mel-18 antibody as in Fig. 5C . To observe the nucleus, cells were also subjected to DAPI staining (blue ; left (10) , and Mel-18 is dominantly expressed in the nucleus (11) whereas Akt is expressed in the cytosol, Mel-18 may regulate Akt activity indirectly by repressing transcription of certain positive regulators of Akt, such as phosphatidylinositol 3-kinase or phosphoinositidedependent kinases, by binding to its target sequences rather than by directly binding to Akt and inhibiting its activity.
Collectively, we propose that Mel-18 acts as a negative regulator of cell cycle in G 1 -S transition through regulation of Akt-mediated cyclin D1 expression and p27
Kip1 phosphorylation at Thr 157 in INK4a/ARF-silenced human breast cancer, and it may suggest the greater possibility of tumor-suppressive activity of Mel-18 in these cancer cells.
